recombinant human acid alpha-glucosidase (rhGAA)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease
Conditions
Pompe Disease, Glycogen Storage Disease Type II, Acid Maltase Deficiency Disease, Glycogenosis 2
Trial Timeline
May 1, 2001 → Sep 1, 2002
NCT ID
NCT00025896About recombinant human acid alpha-glucosidase (rhGAA)
recombinant human acid alpha-glucosidase (rhGAA) is a phase 2 stage product being developed by Sanofi for Pompe Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00025896. Target conditions include Pompe Disease, Glycogen Storage Disease Type II, Acid Maltase Deficiency Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00025896 | Phase 2 | Completed |
Competing Products
20 competing products in Pompe Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 52 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| GZ402666 | Sanofi | Phase 1 | 32 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| glucosidase alfa | Sanofi | Pre-clinical | 22 |
| Alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 84 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 84 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Alglucosidase Alfa + Methotrexate + Rituximab | Sanofi | Approved | 84 |